

NCT01373684 Raw comparison:

Summary:
CHIA has 22 criteria while your personal folder has 23 criteria
Total found criteria: 22/22
Total not Found: 0/22
Total Extra: 1
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Chronic hepatitis B (HBsAg positive > 6 months)    │ Chronic hepatitis B (HBsAg positive \> 6 months)   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ HBeAg negative within six months prior to          │ HBeAg negative within six months prior to          │
│ initiation of peginterferon alfa-2a                │ initiation of peginterferon alfa-2a                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ HBV DNA < 200 IU/ml during nucleos(t)ide analogue  │ HBV DNA \< 200 IU/ml during nucleos(t)ide analogue │
│ (except Telbivudine) treatment within one month    │ (except Telbivudine) treatment within one month    │
│ prior to initiation of peginterferon alfa-2a       │ prior to initiation of peginterferon alfa-2a       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Compensated liver disease                          │ Compensated liver disease                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Age > 18 years                                     │ Age \> 18 years                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Written informed consent                           │ Written informed consent                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Treatment with any investigational drug within 30  │ Treatment with any investigational drug within 30  │
│ days of entry to this protocol                     │ days of entry to this protocol                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current treatment with Telbivudine                 │ Current treatment with Telbivudine                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Severe hepatitis activity as documented by ALT>10  │ Severe hepatitis activity as documented by ALT\>10 │
│ x ULN                                              │ x ULN                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of decompensated cirrhosis (defined as     │ History of decompensated cirrhosis (defined as     │
│ jaundice in the presence of cirrhosis ascites      │ jaundice in the presence of cirrhosis ascites      │
│ bleeding gastric or esophageal varices or          │ bleeding gastric or esophageal varices or          │
│ encephalopathy)                                    │ encephalopathy)                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pre-existent neutropenia (neutrophils <1 500/mm3)  │ Pre-existent neutropenia (neutrophils \<1 500/mm3) │
│ or thrombocytopenia (platelets < 90 000/mm3)       │ or thrombocytopenia (platelets \< 90 000/mm3)      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Co-infection with hepatitis C virus hepatitis D    │ Co-infection with hepatitis C virus hepatitis D    │
│ virus or human immunodeficiency virus (HIV)        │ virus or human immunodeficiency virus (HIV)        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Other acquired or inherited causes of liver        │ Other acquired or inherited causes of liver        │
│ disease alcoholic liver disease obesity induced    │ disease alcoholic liver disease obesity induced    │
│ liver disease drug related liver disease auto-     │ liver disease drug related liver disease auto-     │
│ immune hepatitis hemochromatosis Wilson's disease  │ immune hepatitis hemochromatosis Wilson's disease  │
│ or alpha-1 antitrypsin deficiency                  │ or alpha-1 antitrypsin deficiency                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Alpha fetoprotein > 50 ng/ml                       │ Alpha fetoprotein \> 50 ng/ml                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hyper- or hypothyroidism (subjects requiring       │ Hyper- or hypothyroidism (subjects requiring       │
│ medication to maintain TSH levels in the normal    │ medication to maintain TSH levels in the normal    │
│ range are eligible if all other                    │ range are eligible if all other                    │
│ inclusion/exclusion criteria are met)              │ inclusion/exclusion criteria are met)              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Immune suppressive treatment within the previous 6 │ Immune suppressive treatment within the previous 6 │
│ months                                             │ months                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Contra-indications for alfa-interferon therapy     │ Contra-indications for alfa-interferon therapy     │
│ like suspected hypersensitivity to interferon or   │ like suspected hypersensitivity to interferon or   │
│ Peginterferon or any known pre-existing medical    │ Peginterferon or any known pre-existing medical    │
│ condition that could interfere with the patient's  │ condition that could interfere with the patient's  │
│ participation in and completion of the study       │ participation in and completion of the study       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pregnancy breast-feeding                           │ Pregnancy breast-feeding                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Other significant medical illness that might       │ Other significant medical illness that might       │
│ interfere with this study significant pulmonary    │ interfere with this study significant pulmonary    │
│ dysfunction in the previous 6 months malignancy    │ dysfunction in the previous 6 months malignancy    │
│ other than skin basocellular carcinoma in previous │ other than skin basocellular carcinoma in previous │
│ 5 years immunodeficiency syndromes (e g HIV        │ 5 years immunodeficiency syndromes (e g HIV        │
│ positivity auto-immune diseases organ transplants  │ positivity auto-immune diseases organ transplants  │
│ other than cornea and hair transplant)             │ other than cornea and hair transplant)             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any medical condition requiring or likely to       │ Any medical condition requiring or likely to       │
│ require chronic systemic administration of         │ require chronic systemic administration of         │
│ steroids during the course of the study            │ steroids during the course of the study            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Substance abuse such as alcohol (>80 g/day) I V    │ Substance abuse such as alcohol (\>80 g/day) I V   │
│ drugs and inhaled drugs in the past 2 years        │ drugs and inhaled drugs in the past 2 years        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any other condition which in the opinion of the    │ Any other condition which in the opinion of the    │
│ investigator would make the patient unsuitable for │ investigator would make the patient unsuitable for │
│ enrollment or could interfere with the patient     │ enrollment or could interfere with the patient     │
│ participating in and completing the study          │ participating in and completing the study          │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have minimum age of 18 Years │
╘═══════════════════════════════════╛